Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulgenglucosamine sodium is a form of glucosamine sulfate, often available as a dietary supplement, and is being investigated for its potential therapeutic effects. Its mechanism of action involves inhibiting NF-κB activity, which in turn reduces the gene expression of inflammation and matrix degradation markers. This anti-inflammatory property is believed to contribute to its hypothesized role in managing osteoarthritis by affecting cartilage turnover processes. Emerging research also suggests a potential role in reducing the risk of lung cancer, particularly adenocarcinoma, by interfering with inflammatory pathways. While widely used as a supplement for osteoarthritis, it currently lacks FDA approval as a pharmaceutical drug for any indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulgenglucosamine sodium.